Company · founded 1998

Microbiotix (United States)

Worcester, United States · microbiotix.com

Manage this page

Citations, last 5 years: 65
Works, last 5 years: 16
h-index: 80
Scientists listed: 5
Grants since 2016: 69

Grants received

2025–2027 · research · R41

Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$299.9k

2025–2027 · research · R43

Development of well tolerated novel Inhibitors of drug resistant CMV

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$298.6k

2025–2028 · research · R33

Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$675k

2024–2026 · research · R41

Proof of concept experiments for T3SS inhibitors against burn wound infections

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$300k

2024–2026 · research · R41

Proof of concept experiments for T3SS inhibitors against burn wound infections

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$300k

2023–2025 · research · R43

Development of antibody drug conjugates as pan-filo antivirals

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$300kViral Infections and Outbreaks Research

2023–2025 · research · R43

Development of antibody drug conjugates as pan-filo antivirals

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$286.7kViral Infections and Outbreaks Research

2022–2024 · research · R41

Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy

Gaya K. Amarasinghe · Microbiotix (United States) · funded by National Institutes of Health

$296.5kViral Infections and Vectors

2022–2023 · research · R43

Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$300.2k

2022–2023 · contract · N01

DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$2.1M

2022–2025 · research · R41

Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy

Gaya K. Amarasinghe · Microbiotix (United States) · funded by National Institutes of Health

$272.1kViral Infections and Vectors

2022–2027 · contract · N01

DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$2.9M

2022–2028 · research · R42

Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral

Gaya K. Amarasinghe · Microbiotix (United States) · funded by National Institutes of Health

$977.4k

2021–2024 · research · R44

Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$712.8kVirus-based gene therapy research

2021–2023 · research · R44

Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$749.5kVirus-based gene therapy research

2020–2022 · research · R43

Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$298.5kHepatitis B Virus Studies

2020–2022 · research · R41

Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

Alejandro Pablo Heuck · Microbiotix (United States) · funded by National Institutes of Health

$299.4k

2020–2021 · contract · N01

Development of Therapeutic Products for Antibiotic Resistant Bacteria

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$904.9k

2020–2024 · contract · N01

Development of Therapeutic Products for Antibiotic Resistant Bacteria

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$830.9k

2020–2024 · research · R41

Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

Alejandro Pablo Heuck · Microbiotix (United States) · funded by National Institutes of Health

$300k

2020–2025 · contract · N01

Development of Therapeutic Products for Antibiotic Resistant Bacteria

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$2.5M

2020–2023 · research · R43

Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$298.3kHepatitis B Virus Studies

2020–2022 · contract · N01

Development of Therapeutic Products for Antibiotic Resistant Bacteria

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$299.6k

2020–2023 · research · R43

Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis

Islam Hussein · Microbiotix (United States) · funded by National Institutes of Health

$286.7kViral Infections and Immunology Research

2020–2022 · research · R43

Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis

Islam Hussein · Microbiotix (United States) · funded by National Institutes of Health

$298.5kViral Infections and Immunology Research

2020–2026 · contract · N01

Development of Therapeutic Products for Antibiotic Resistant Bacteria

Terry Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$2.7M

2019–2022 · research · R43

Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$300kViral Infections and Immunology Research

2019–2021 · research · R43

Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$300kViral Infections and Immunology Research

2018–2020 · research · R41

Discovery of Zika virus therapeutics using a replicon assay

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$300kMosquito-borne diseases and control

2018–2020 · research · R43

Synergistic panfiloviral entry inhibiting antibody drug conjugates

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$300kViral Infections and Outbreaks Research

2018–2020 · research · R43

Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$296.2kViral Infections and Outbreaks Research

2018–2020 · research · R43

EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$297.2kReproductive tract infections research

2018–2021 · research · R43

Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$297.6kMosquito-borne diseases and control

2018–2020 · research · R43

Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$300kMosquito-borne diseases and control

2018–2021 · research · R41

Discovery of Zika virus therapeutics using a replicon assay

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$285kMosquito-borne diseases and control

2018–2019 · research · R43

Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy

Gai Liu · Microbiotix (United States) · funded by National Institutes of Health

$299.4kViral Infections and Outbreaks Research

2018–2022 · research · R43

Synergistic panfiloviral entry inhibiting antibody drug conjugates

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$300kViral Infections and Outbreaks Research

2018–2020 · research · R43

EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$299.7kReproductive tract infections research

2017–2022 · research · R01

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$1.1MReproductive tract infections research

2017–2019 · research · R43

Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$299.3kAntibiotic Resistance in Bacteria